Safety and Efficacy of Oral DMSA Therapy for Children with Autism Spectrum Disorders: Part A – Medical Results
![round clear glass on white paper](https://i0.wp.com/canadahealthalliance.org/wp-content/uploads/2023/04/jxqtaxf5wmy-1.jpg?fit=800%2C534&ssl=1)
James B. Adams Background: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years. Methods: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase […]
Safety and Efficacy of Oral DMSA Therapy for Children with Autism Spectrum Disorders: Part B – Behavioral Results
![round clear glass on white paper](https://i0.wp.com/canadahealthalliance.org/wp-content/uploads/2023/04/jxqtaxf5wmy-1.jpg?fit=800%2C534&ssl=1)
James B. Adams et al. Background: This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years. Methods: Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of […]